Breast Cancer

Data also show statistically meaningful improvements in endocrine symptoms and breast cancer–specific quality of life with acupuncture.

The new recommendation update modifies a 2020 ASCO guideline on the selection of optimal adjuvant chemotherapy and targeted therapy for breast cancer.

A ready-to-dilute formula of SH-105 has been approved by the FDA to treat breast and ovarian cancers.

Updated results from the POSITIVE trial found that patients younger than 35 years had a higher likelihood of achieving pregnancy during an endocrine therapy pause for HR-positive breast cancer.

Paolo Tarantino, MD, discusses the potential utility of agents such as datopotamab deruxtecan and enfortumab vedotin in patients with breast cancer.

Paolo Tarantino, MD, highlights strategies related to screening and multidisciplinary collaboration for managing ILD in patients who receive T-DXd.

Data from CAPItello-291 support the approval of capivasertib/fulvestrant for ER-positive, HER2-negative breast cancer in the European Union.

Capivasertib's safety profile in the CAPItello-290 trial was comparable with prior reports of the agent in advanced triple-negative breast cancer.

Neil M. Iyengar, MD, and Paolo Tarantino, MD, discuss updated data on agents such as T-DXd and abemaciclib in breast cancer presented at 2024 ASCO.

Patients with hormone receptor-positive breast cancer experienced weight loss when given a plant-based diet plus exercise.

The field of breast oncology is constantly evolving to include trial diversity and multidisciplinary care.

Tiffany A. Traina, MD, and Sherry Shen, MD, discussed barriers they have had to overcome throughout their oncology careers.

Patients with breast cancer or those who are survivors can be candidates for genetic testing, according to Brittany L. Bychkovsky, MD, MSc.

Secondary end points such as overall survival also appear to favor T-DXd among this breast cancer population in the phase 3 DESTINY-Breast06 trial.

Data also show a longer median time to deterioration for patients in the inavolisib arm in phase 3 INAVO120 trial.

A trend towards improved progression-free survival was not noted when pembrolizumab plus sacituzumab govitecan was used to treat patients with HR+ breast cancer.